Analyst Price Target is $51.50
▲ +32.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Twist Bioscience in the last 3 months. The average price target is $51.50, with a high forecast of $56.00 and a low forecast of $45.00. The average price target represents a 32.42% upside from the last price of $38.89.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Twist Bioscience. This rating has held steady since January 2022, when it changed from a Hold consensus rating.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.